Shared Genetic Factors Drive Much of the Overlap Between Alcohol, Tobacco, and Cannabis Dependence ↗
Twin study found over 60% of the shared vulnerability to alcohol, tobacco, and cannabis dependence was driven by common genetic factors.
Browse more cannabis research, findings, methods, and limitations.
Twin study found over 60% of the shared vulnerability to alcohol, tobacco, and cannabis dependence was driven by common genetic factors.
In rats, caffeine did not offset THC's memory effects but actually worsened them, with a subthreshold THC dose impairing memory when combined with caffeine.
Comprehensive review found the brain's endocannabinoid system plays a key role in alcohol's rewarding effects and is altered by chronic drinking.
Review identified five strategies for making cannabinoid medicines more effective while reducing psychoactive side effects, covering applications from pain to neurodegeneration.
Review found nabiximols (THC/CBD spray) effectively treated spasticity, pain, and bladder dysfunction in MS, though long-term data were limited.
Review found cannabinoids may both relieve MS spasticity symptoms and protect nerve cells from disease-related damage.
The endocannabinoid system is active in embryos before brain development begins, suggesting early pregnancy cannabis exposure could disrupt fundamental developmental processes.
High-intensity running raised blood endocannabinoids in humans and dogs, not in ferrets and not during walking.
A single dose of CBD reduced lung inflammation across multiple markers in mice, working through the adenosine A2A receptor pathway.
CBD suppressed vomiting and nausea-like behavior in animals by activating serotonin 5-HT1A receptors in a specific brainstem region.
Brain imaging found chronic cannabis users had altered activation in social cognition regions, matching patterns seen in psychosis-risk populations.
Depression and insight measures distinguished cannabis-induced psychosis from primary psychotic disorders with 97% accuracy in hospitalized patients.
Preclinical evidence showed cannabinoids, especially the THC/CBD combination in Sativex, had neuroprotective properties relevant to Huntington's disease.
Cannabinoid agonists injected directly into muscles reduced pain in rats, with local administration outperforming systemic in one of two models tested.
Only 0.7% of Italian workers in safety-sensitive jobs tested positive for drugs, likely because the law requires them to be notified the day before testing.
Cannabis improved verbal fluency in people with low baseline creativity while increasing psychosis-like symptoms in all users.
Eighteen months of heroin treatment reduced heroin, cocaine, and benzodiazepine use, but cannabis and alcohol consumption remained unchanged.
Alcohol withdrawal reduced endocannabinoid system gene expression in the rat amygdala, with repeated withdrawal cycles causing worse disruption.
Largest early CH series: frequent long-term use common, abdominal pain prevalent, 91 percent of those who tried hot bathing reported relief. Follow-up was scarce.
Overview described the endocannabinoid system as a master regulator involved in neuroprotection, pain, memory, neurogenesis, and immune function.
South African survey found high stigma toward all substance users, but cannabis was rated less dangerous than alcohol, and men faced more coercive attitudes than women.
Among 457 fibromyalgia patients, 13% used cannabinoids, with herbal cannabis use linked to mental illness, opioid drug-seeking, and male sex.
Former cannabis users recovered associative learning ability but still showed impaired response timing, suggesting lasting cerebellar changes after quitting.
Early cannabis use was linked to a 2.9-fold increased risk of suicide attempt in French students, with different substance-suicide patterns across France and the US.
Longitudinal study found the order of trying drugs did not predict cannabis use disorder; peer influence was the key factor.
Adolescent THC exposure in rats altered gene regulation through epigenetic changes in the reward system, directly increasing vulnerability to heroin self-administration.
A THC/CBD combination reduced brain cell death and inflammation in a rat Huntington's disease model, working through both CB1 and CB2 receptors.
Review found effective medications for nicotine, alcohol, and opioid dependence, but none approved for cannabis or cocaine dependence.
Blocking cannabinoid receptors improved memory deficits during morphine withdrawal in mice, with chronic treatment being more effective than a single dose.
THC selectively impaired spatial but not object working memory in adolescent monkeys, suggesting less mature brain functions are more vulnerable.
A study of 7,452 twins found none of 10 previously reported cannabis-associated genes replicated, suggesting earlier findings were likely false positives.
Oral fluid testing detected all drug types found in blood among 100 suspected drug drivers, offering a faster alternative to urine collection.
Twin study found shared genetic risk for nicotine, alcohol, and marijuana peaked at ages 14-17 and declined into adulthood as substance use became more environmentally driven.
Safety review found Sativex was well-tolerated for MS spasticity with no evidence of dependence, dose escalation, or significant withdrawal upon stopping.
CB1-expressing neurons in the brain's reward center are fast-spiking interneurons that become hyperexcitable during cocaine withdrawal, potentially suppressing reward circuit output.
Research tools for boosting brain endocannabinoids work differently in rats versus mice, with FAAH and MAGL inhibitors selectively targeting anandamide or 2-AG respectively.
Spinal administration of an enzyme inhibitor powerfully reduced pain signaling and blocked inflammation-induced sensitization in rats via endocannabinoid mechanisms.
Analysis of 666 patients in three Sativex trials found no evidence of unblinding, confirming the validity of self-reported efficacy results.
Meta-analysis found schizophrenia patients who used cannabis had better cognitive performance than non-using patients, suggesting a different pathway to psychosis.
Phase III trial found oral cannabis extract nearly doubled muscle stiffness relief compared to placebo in 279 MS patients, with benefits for pain and sleep.
Systematic review of 34 human studies found preliminary CBD benefits for anxiety, insomnia, and epilepsy, with complex THC interactions depending on delivery route.
Survey of 37 medical cannabis patients found elevated psychological distress and widespread exposure to drug law enforcement tactics.
Brain imaging showed heavy cannabis users activated habit-related brain regions for positive cannabis associations while non-users activated deliberate control regions.
Pregabalin and topiramate both reduced anxiety and motor symptoms during cannabinoid withdrawal in mice while reversing brain gene expression changes.
Four-year study of 1,145 college students found cannabis use predicted late enrollment gaps while depression predicted early ones.
Study of 984 college students found "study drug" use was linked to escalating cannabis and alcohol problems and declining academic performance, not academic ambition.
About half of healthy men experienced psychotic symptoms from THC while half did not, with distinctly different brain activation patterns between groups.
Veterans with poor perceived sleep quality reduced their cannabis use less during a 6-month quit attempt, even after accounting for PTSD and withdrawal.
Brain imaging showed cannabis disrupted attention and executive control networks while increasing self-focused brain activity, even at low blood THC levels.
First group cessation program for simultaneous tobacco and cannabis quitting was developed through user research and received positive acceptability ratings.